Background: Tissue factor pathway inhibitor-2 (TFPI-2) is a serine protease inhibitor that exerts multiple physiological and patho-physiological activities involving the modulation of coagulation, angiogenesis, tumor invasion, and apoptosis. In previous studies we reported a novel role of human TFPI-2 in innate immunity by serving as a precursor for host defense peptides. Here we employed a number of TFPI-2 derived peptides from different vertebrate species and found that their antibacterial activity is evolutionary conserved although the amino acid sequence is not well conserved. We further studied the theraputic potential of one selected TFPI-2 derived peptide (mouse) in a murine sepsis model.
Background
In response to pathogenic microorganisms, host organisms have evolved a diverse range of defense mechanisms, starting from simple mechanical barriers to complex immune systems. In these processes, blood coagulation, complement cascades and antimicrobial peptides are central to host defense and many components of these systems are evolutionary conserved [1] . The crosstalk between the coagulation and complement systems is essential for the clearance of the infection. Together they have a dual role of immobilization and destruction of invading bacteria in addition to preventing the loss of body fluids. Coagulation factors, apart from their primary role of maintaining hemostasis, are also involved in killing of bacteria and immunomodulation, such as thrombin [2] , kininogen [3] , protein C inhibitor [4] , fibrinogen [5, 6] , antithrombin [7] , TFPI-1 [8] , and TFPI-2 [9, 10] . These proteins may explore their activities either as intact molecules or after proteolysis. Often they execute their host defense functions by killing the intruder or by triggering immunomodulatory reactions. Many well-characterized antimicrobial peptides have recently been found to exhibit also multifaceted immunomodulatory activities, such as reported for LL-37 [11, 12] and some antimicrobial peptides have been described to be involved in angiogenesis, chemotaxis, and wound-healing [11] . These biological properties suggest that host defense peptides may have a clinical potential also in disorders where targeting of inflammatory pathways is beneficial, such as in sepsis [11, 13] .
Tissue factor pathway inhibitor 2 (TFPI-2) consists of a highly negatively charged N-terminal region, three tandemly linked Kunitz-type domains, and a highly positively charged C-terminus [14, 15] . The molecule is synthesized and secreted by many cells, including skin fibroblasts, endothelial cells (ECs), smooth muscle cells (SMCs), dermal fibroblasts, keratinocytes, monocytes, macrophages and syncytiotrophoblasts [16, 17] . In vitro, TFPI-2 is a weak inhibitor of coagulation induced by the TF-VII complex, while it targets a wide range of proteases such as trypsin, chymotrypsin, plasmin, MMPs, factor XIa and plasma kallikrein [18, 19] . Stimulation of human umbilical vein endothelial cells with inflammatory mediators such as PMA, LPS, or TNF-α significantly increases TFPI-2 expression [17] . Analogously, in a murine model, TFPI-2 expression is dramatically upregulated in the liver upon LPS stimulation [20] . Notably, it has been shown that proteases such as ADAMTS1, plasmin and thrombin can process TFPI-2 at its C-terminal end in in vitro experiments [21] . We previously reported an undisclosed host defense function of the C-terminal region of TFPI-2 [9, 10] . TFPI-2 as well as the C-terminal peptides of the molecule were detected in wounds from patients and were found in complex with the bacteria and fibrin. Correspondingly, human TFPI-2 was degraded in vitro by human neutrophil elastase, leading to the generation of Cterminal TFPI-2 fragments. These fragments were then found to bind to various bacterial surfaces, kill gramnegative bacteria, through membrane lysis, and boost complement activation, including formation of the membrane attack complex (MAC) and antimicrobial C3a. In a therapeutic context, the peptide significantly reduced mortality either as a monotherapy, or in combination with ceftazidime E. coli and P. aeruginosa sepsis models. We therefore hypothesized that TFPI-2 C-terminal derived peptides may have an important function in the host defense to infection, thus they may be interesting agents for drug development.
Results
Phylogenetic and sequence analysis of the TFPI-2 C-terminal part from different species A phylogenetic tree was constructed with C-terminal TFPI-2 sequences from 72 vertebrate organisms, using neighbor-joining method with 1000 bootstrap repeats, resulting in distinct groups (Fig. 1 ). The remainder of TFPI-2 and full length protein are more conserved than the C-terminal region, at first suggesting that the Cterminal region has not been under evolutionary pressure (Additional file 1: Figure S1 ). Even though the TFPI-2 amino acid length varies among the species, many other conserved regions were observed among the species (data not shown). Interestingly, the multiple sequence alignment of the C-terminal antimicrobial peptide region is not fully conserved (Fig. 2 ). Importantly however, even though the C-terminal region was not well conserved, the net positive charge is preserved, with a charge ranging from +7 to +14 (Table 1 ). This suggests an important role of the charge and points towards putative antimicrobial activity where charge rather than the exact amino acid sequence is essential.
Antimicrobial activities of TFPI-2 C-terminal derived peptides
Having identified the C-terminal region of TFPI-2, we next wished to investigate whether other vertebrate derived peptides retain similar bactericidal activity compared to the human peptide. The antimicrobial properties of the C-terminal TFPI-2 derived peptides from different vertebrates were assessed using radial diffusion assay against gram-negative bacteria E. coli and P. aeruginosa (Fig. 3 ). These species included primates (human and gorilla), rodents (mouse), birds (turkey and chicken), reptiles (alligator and turtle), amphibians (frog) and fishes (shark and zebra fish). We also noted that all vertebrate peptides displayed antimicrobial activities at concentrations of 100 μM against both bacteria. In consensus with the human peptide, we investigated if also other vertebratederived peptides display enhanced bactericidal activity in presence of plasma. To this end, the peptides were incubated at varying concentrations with E. coli in presence of physiological buffer containing 20 % human citrate plasma, since this E. coli strain is complement sensitive. In concordance with previous data, all vertebrate peptides displayed enhanced bactericidal activity against E. coli. Complete bacterial killing was observed at a concentration of 1 μM in human plasma, which is due to boosting complement activation, whereas higher concentrations of the peptides were required for their direct antimicrobial activity as seen from incubating the peptide in presence of buffer ( Fig. 4 ). The growth of bacteria in buffer is slower than in citrated plasma, but the peptide-mediated killing in buffer is still less efficient than in citrated plasma.
Effect of TFPI-2 derived peptides on blood coagulation/ intrinsic pathway of coagulation
Previously, it was shown that the human TFPI-2 derived peptide EDC34 blocks the intrinsic pathway of coagulation in both human and murine plasma [22] . Based on these findings we investigated the anticoagulant activity of the vertebrate-derived TFPI-2 peptides by determining the prolongation of activated partial thromboplastin time (aPTT). As shown in Fig. 5a , all peptides effectively prolonged the normal clotting time on aPTT by more than 100 s when applied at a concentration of 50 μM. We further noted that all vertebrate-derived anticoagulant peptides tested are non-hemolytic at 60 μM and thus have potential to be used in therapeutic applications ( Fig. 5b ).
Mouse C-terminal TFPI-2 derived VKG24 peptide provides protection against septic shock Given the observed effects of the TFPI-2 C-terminal peptides, we made an attempt to find out whether these peptides are of therapeutic importance. To test whether the endogenous C-terminal TFPI-2 region is important in host defense, the mouse peptide VKG24 was chosen for a murine in vivo model. In vitro, VKG24 peptide displayed potent antimicrobial and anti-coagulant activities in mouse plasma (Additional file 2: Figure S2 ). Thus, the in vivo efficiency of VKG24 peptide was evaluated in a standardized mouse model of endotoxin-induced shock [22] . A dramatic improvement in the survival rate of the animals was seen after treatment with the peptide (~25 mg/kg body weight) ( Fig. 6a ). Peptide-treated animals started regaining their weight from day three ( Fig. 6b ). Previous studies have shown that thrombocytopenia is as an important indicator for the severity of sepsis and disseminated intravascular coagulation [23] . Therefore, activation of the intrinsic and extrinsic coagulation pathways was measured in citrate plasma of LPS-injected mice that received a VKG24 injection or were left untreated. The treatment showed significantly decreased coagulation aPTT and PT times in LPS challenged mice, indicating that the peptide reduced consumption of coagulation proteins (Fig. 6c ). The levels were completely normalized in the survivors after seven days. Analyses of the cytokine profile 24 h after LPS injection showed significant reduction of IL-6, MCP-1, IFN-γ and IL-10, respectively ( Fig. 6d ). Thus, the results demonstrate that the mouse VKG24 peptide exerts potent immunomodulatory activity.
Discussion
In the present study we aimed to study the host defence and immunomodulatory activities of the vertebrate Cterminal epitope of TFPI-2. Sequence analysis of this region in different vertebrate species showed that the exact amino acid sequence was not well conserved, whereas the net positive charge appeared to be preserved. These findings suggest an essential function of the charge. It can be speculated that there has been an evolutionary pressure to maintain the positive charge in the Cterminal region, as this is important in the host defence against bacterial pathogens. Within the last years, TFPI-2 has attracted increasing attention because of its ubiquitous presence, which leads to the deposition in a variety of tissues and particularly in the extracellular matrix. This likely reflects its potential as a central regulator of multiple biological processes involving the control of inflammatory reactions, matrix protease activity, coagulation, angiogenesis, and tumour growth. In previous studies we found that the proteolysis of human TFPI-2 generates C-terminal fragments, both in vivo and in vitro after digestion with neutrophil elastase. These findings are of importance in the context of proteolysis of TFPI-2 and possible release of bioactive host defence fragments [9, 10] . Notably, the observed generation of C-terminal fragments of TFPI-2 are very similar to that seen with TFPI-1, suggesting that the same cleavage sites is used by plasmin and thrombin to generate the C-terminal part of TFPI-1. Interestingly, previous data on TFPI-1 and TFPI-2 revealed that the release of C-terminal peptides may exert similar complement boosting effects [8] [9] [10] . It is also notable that the Cterminal peptide of TFPI-1, GGL27, and TFPI-2, EDC34 prolongs aPTT, thus further illustrating a functional overlap between the two TFPI proteins. In a broader perspective, a picture thus emerges; suggesting that Cterminal fragments from both TFPI-1 and TFPI-2 may be released during inflammation and infection, serving as modulators of both antimicrobial activity and coagulation. So far, available structural and functional data [24] as well as human kininogen, all displaying mostly random coil conformation in buffer and at lipid bilayers, the interactions dominated by electrostatic interactions [25] . It remains to be investigated whether TFPI-2 peptides may have similar actions as those reported here, although the absence of a marked boosting of activity in plasma suggests that complement interactions are characteristic for the TFPI-peptides. The detailed mode of action of these peptides remains to be explored, but it seems that they are involved in interactions with C1q and/or other molecules that can initiate the classical pathway of complement and lead to the formation of C3a or a MAC complex. Contact activation, involving degradation of human kininogen, and release of vasoactive bradykinin has been reported during various infective processes including sepsis [26, 27] . The finding that EDC34 inhibited contact activation in vitro is of importance, since a generalized activation of the system can be deleterious.
From a clinical perspective, many opportunistic bacteria can cause both localized and systemic infections and are responsible for considerable mortality or morbidity in patients suffering from burn wound infections, pneumonia, cystic fibrosis, intra-abdominal infections, chronic ulcers, and sepsis. Our results show a direct antimicrobial activity of the TFPI-2 peptide derived from different vertebrates species. The potent antimicrobial activity of these peptides was paired with boosting of complement activation and a modulation of the coagulation cascade. In vivo, VKG24 administration after LPS challenge protects mice and also significantly reduced aPTT and PT time. Therefore, our findings that VKG24 is able to significantly reduce LPS induced shock is particularly relevant, and implies a therapeutic potential for VKG24. The protective effect of mouse VKG24 in infections caused by Gram-negative pathogens may also apply to other vertebrate TFPI-2 Cterminal peptides.
Conclusions
Several therapeutic strategies to combat severe infections including sepsis are based on supplementation of antibiotics with molecules exerting anti-coagulant and anti-inflammatory actions [28] . The dual effects of these natural peptides, for example the mouse derived VKG24 peptide, that can block contact activation and boost complement activation, thus represent, to our knowledge, a novel treatment concept, which could enable complement mediated bacterial clearance while inhibiting the deleterious effects of excessive procoagulant responses during infection with Gramnegative bacteria.
Methods

Peptides
Indicated peptides (Additional file 3: Table S1 ) were synthesized by Ontores (Shanghai, China). The purity (>98 %) Fig. 3 Antimicrobial activities of TFPI-2 C-terminal derived peptides from different species. For determination of antimicrobial activities, E. coli ATCC 25922 and P. aeruginosa ATCC 27853 (4 × 10 6 cfu) were inoculated in 0.1 % TSB agarose gel. Each 4 mm-diameter well was loaded with 6 μl of peptide (at 100 μM). The zones of clearance (in mm) correspond to the inhibitory effect of each peptide after incubation at 37°C for 18-24 h (mean values are presented, n = 3). A control with buffer only yielded no inhibition zone of these peptides was confirmed by mass spectral analysis (MALDI-ToF Voyager).
Microorganisms
The bacterial isolates E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were obtained from the American Type Culture Collection.
Radial diffusion assay (RDA)
Essentially as described earlier, bacteria were grown to mid-logarithmic phase in 10 ml of full-strength (3 % w/v) trypticase soy broth (TSB) (Becton-Dickinson, Cockeysville, MD). The microorganisms were then washed once with 10 mM Tris, pH 7.4. Subsequently, 4 × 10 6 bacterial colony forming units (cfu) were added to 15 ml of the underlay 
Viable count analysis (VCA)
E. coli were grown to mid-exponential phase in Todd-Hewitt (TH). Bacteria were washed and diluted in 10 mM Tris, pH 7.4 either alone or with 20 % human or mouse (BALB/c) citrate-plasma. Bacterial (2 × 10 6 cfu/ml) were incubated in 50 μl, at 37°C for 1 h with the Cterminal TFPI-2 derived peptides at the indicated concentrations. Serial dilutions of the incubation mixture were plated on TH agar, followed by incubation at 37°C overnight and cfu determination.
LPS animal model
Male/female balb/c mice (8 weeks, 21 ± 5 g) were injected intraperitoneally (i.p.) with 10 mg E. coli 0111:B4 LPS (Sigma) per kg of body weight. Thirty minutes after LPS injection, 0.5 mg VKG24 (25 mg/kg) or PBS buffer alone (control) were injected i.p. into the mice. Status and weight were monitored daily for seven days. Mice where immobilization and/or shaking was observed were euthanized by an overdose of isoflurane (Abbott) and counted as non-survivors. For determination of cytokine levels in mouse plasma, animals were sacrificed 24 h after LPS injection. The blood was collected immediately by cardiac puncture into citrate tubes.
Cytokine assay
Cytokines IL-6, IL-10, MCP-1, INF-γ and TNF-α were measured in plasma from mice infected by E. coli LPS (with or without peptide treatment) using the Cytometric bead array; mouse inflammation kit (Becton Dickinson AB) according to the manufacturer's instructions. All plasma samples were stored at −80°C before the analysis.
Hemolysis assay
EDTA-blood was centrifuged at 800 × g for 10 min, where after plasma and buffy coat were removed. The erythrocytes were washed three times and resuspended in PBS, pH 7.4 to get a 5 % suspension. The cells were then incubated with end-over-end rotation for 60 min at 37°C in the presence of peptides (60 μM). Triton X-100 (Sigma) 2 % served as positive control. The samples were then centrifuged at 800 × g for 10 min and the supernatant was transferred to a 96 well microtiter plate. The absorbance of hemoglobin release was measured at 540 nm and expressed as percentage of Triton X-100 induced hemolysis.
Phylogenetic and sequence homology analyses
Various vertebrate TFPI-2 amino acid sequences, which are presently available, were retrieved from the NCBI, Ensembl and Uniprot. These sequences were aligned using Blosum 69 protein weight matrix settings using BioEdit software (Ibis Biosciences, Carlsbad, CA). Internal adjustments were made taking the structural alignment into account utilizing the ClustalW interface. Neighbor-joining method was used for phylogenetic tree construction, and the reliability of each branch was assessed using 1000 bootstrap replications using Mega-6.
Clotting assays
All clotting times were analyzed using a coagulometer (Amelung, Lemgo, Germany). For determination of activated partial thromboplastin time (aPTT), 100 μl of a kaolin-containing solution (Technoclone) was added to the 100 μl of fresh citrate plasma or citrate plasma peptide mix and incubated at 37°C for 200 s before clot formation was initiated by adding 100 μl of 30 mM fresh CaCl 2 solution. For detection of prothrombin time (PT, thromboplastin reagent (Trinity Biotech)) 100 μl of fresh citrate plasma were incubated 60 s at 37°C before clot formation was initiated by adding 100 μl of clotting reagent.
Statistical analysis
Values are shown as mean with SEM. For statistical evaluation of two experimental groups, one-way with Tukey's multiple comparisons post-test was used and for comparison of survival curves the Mantel-Cox's test. Viable count and radial diffusion assay data are presented as mean with SD. All statistical evaluations were performed using the GraphPad Prism software 6.0 with *p-< 0.05, **p-< 0.01, *** < 0.001, ****p < 0.0001 and ns = not significant. Fig. 6 Treatment of LPS-induced septic shock mice with a mouse TFPI-2 derived peptide. Septic shock in Balb/c mice was induced by i.p. injection of 10 mg/kg E. coli LPS. Thirty minutes after LPS injection, VKG24 (0.5 mg/mouse or~25 mg/kg body weight) or PBS was administrated i.p. a Mouse TFPI-2 derived peptide significantly increased survival of mice. Survival of mice was monitored for 7 days (only the first 96 h is shown in the figure). Statistical comparisons of survival curves were performed using the Mantel-Cox's test. ***P ≤ 0.0003. b Weight was determined daily. c Clotting times of aPTT and PT was measured in citrate plasma 24 h after LPS injection (n = 8). d The indicated cytokines were analyzed in plasma 24 h after LPS injection (n = 8). Statistical analysis for C-D, one-way ANOVA with Tukey's multiple comparisons post-test was used. **P ≤ 0.003, ****P ≤ 0.0001
